Clinical Trial Search

Primary: Percent of Participants Achieving Sustained Remission at Week 36 — 4.0; 18.2 Estimated Percentage of Participants — p=0.0250

Primary: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters. — 6 weeks

Primary: Primary Safety Endpoint — 0; 0; 1 participants

Primary: Cessation of Blister Formation — NA days

Primary: Number of Participants With Anti-Drug Antibodies — 0 Participants

Primary: Number of Participants With CRoff at Week 36 — 8; 2 Participants

Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00

Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants

Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants

Primary: Percentage of Participants With Treatment-emergent Adverse Events — 74.1; 86.7; 11.1; 0 percentage of participants

Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…

Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008

Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1

Primary: Percentage of Patients Achieving Responder Status at Week 52 — 63.9; 69.0 Percentage of Participants — p=0.6558

Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale

Primary: Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage — 57.25; 39.40; 27.25; 25.45 percentage of BSA involvement

Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants

Primary: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy — 44; 20 Participants

Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares

Primary: Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment — 45; 33 Participants — p=0.013

Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale

Primary: Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment — 8; 6; 7; 7 Participants — p==0.3699

Primary: Percentage of Patients With Adverse Reactions, Defined as Drug-related Adverse Events (AE) — 57.1 percentage of participants

Primary: Time To Complete Target Wound Closure Within 3 Months — 41.6; 53.6 days — p=0.985

Primary: Treatment-emergent Adverse Events — 40 Participants

Primary: Percentage Change in Palmoplantar Pustulosis Severity Index (PPPASI) Before Crossover — 30.1; 7.1 Percentage change

Primary: Number of Subjects Reported at Least One Adverse Event, Safety Population — 9 Participants

Primary: Percentage of Wound Surface Area Change From Baseline to Week 8 — -63; -8.1 percentage of wound surface area

Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…

Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds